Deliver logo

Clinical Development of CAR T cell Therapy and Next Generation CAR T cells
-- Define the concept of CAR T cell therapy for cancer
-- Summarize clinical outcomes of CAR T cell trials
-- Recognize barriers to CAR T therapy of cancer and highlight novel approaches to overcome these barriers
-- Recognize novel CAR T cell designs utilized to optimize anti-cancer efficacy of this novel approach as well as how these armored CAR T cell designs may bridge the gap from liquid to solid tumors
Prof. Renier Brentjens, Director, Cellular Therapeutics; Associate Chair, Junior Faculty Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center

Towards safer, more effective and persistent T-cell therapies: Development of antibody-TCR (AbTCR) expressing T cells against solid and hematological malignancies
-- Major barriers of current CAR-T – CRS and neurotoxicity risks
-- ARTEMIS AbTCR T-cell Receptor Platform intro
-- Safety validation of ARTEMIS platform in CD19+ NHL
-- Eureka built a versatile structure to go after solid tumor by using a TCRm antibody on ARTEMIS platform
-- Safety and efficacy validation in AFP+ HCC is achieved
-- Future directions to expand the ARTEMIS platform
Dr. Cheng Liu, Founder and Chief Executive Officer, Eureka Therapeutics

Advances in CAR T cell therapy for Multiple Myeloma
-- BCMA targeted CAR T cell therapy has dramatic efficacy in heavily pre-treated patient population, but relapse is common
-- Potential causes of relapse: Antigen escape, anti-CAR immunity, lack of CAR T cell expansion/functional persistence
-- Addressing relapse: Targeting additional antigens, human CAR, optimized CAR design
Dr. Eric Smith, Director Translational Development, Cellular Therapeutics Center; Assistant Attending, Myeloma Service, Memorial Sloan Kettering Cancer Center

Towards First-in-Class Anticancer Drugs With New Mechanism of Action
-- Histone acetyltransferases (HATS) were thought to be an “undruggable” target class
-- We have developed potent inhibitors, proving that HATS can be “drugged”
-- Baell et al, Nature 560 (2018) 253-257
-- Our patented compounds represent a licensing opportunity
-- Other opportunities for translating excellent Australian biomedical research will be briefly discussed
Prof. Jonathan B. Baell, NHMRC Principal Research Fellow, Director, Australian Translational Medicinal Chemistry Facility, Larkins Fellow, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus)

Primary and Secondary Mechanisms of Resistance to Anti-CD19 CAR T cell Therapy in NHL
-- Product related
-- Tumor microenvironment related
-- Loss of target
Dr. John Rossi, Director, Translational Medicine, Kite, A Gilead Company

Precision Immunotherapy: CAR T-Cell Therapy for Multiple Myeloma -- The Development Story of LCAR-B38M
Abstract: Legend Biotech has successfully developed a proprietary multi-specific CAR-T platform which differentiate the company from all other CAR-T companies in the world. The innovative CAR-T technology platform applied Camelid single domain antibodies as antigen binding domain in the CAR design and it demonstrated significant clinical benefit in terms of safety and efficacy. Multiple Myeloma had been largely considered an incurable cancer in the field of hematologic malignancy. Dr Fan’s group not only proved that BCMA molecule is one of the best CAR-T target for treating multiple myeloma, but also designed an innovative bi-epitope targeting CAR-T modality in which myeloma cell surface BCMA molecule be captured by the CAR-T cells at two different epitopes simultaneously, thus effectively prevent the cancer cell from escape. The LCAR-B38M CAR-T cells had been proven to be the best-in-class therapy for multiple myeloma via an investigator initiated clinical trial conducted in China. The innovative product became the first cell therapy product obtained the first ever IND certificate for CAR-T cell product in China. Johnson & Johnson has entered into a worldwide collaboration and license agreement with Legend Biotech to co-develop the world market of the product.
Dr. Frank Fan, Chief Scientific Officer and Co-Founder, Legend Biotech

Stage Appropriate CAR T Manufacturing and How to Plan a Facility for It
-- How to assess in house manufacturing versus outsourcing
-- The importance of process development and how it relates to facility design
-- What to consider when building out a manufacturing facility
Dr. Knut Niss, Chief Technology Officer, Mustang Bio

Industrializing Cell & Gene Therapies: Managing Complexity Across the Ecosystem
-- Cell and gene therapies hold tremendous clinical promise but are complex and costly
-- Dealing with patient heterogeneity and treatment histories complicates manufacturing
-- The supply chain has many steps, but new technologies are emerging to improve efficacy and manufacturing efficiency
-- Data collection, analytics, and automation will help scale manufacturing of cell and gene therapies
Dr. Philip G. Vanek, GM, Cell and Gene Therapy Strategy, GE Healthcare

Towards commercialization – accomplish the challenges of autologous cell and gene therapies
-- Control strategies for cell and gene therapies
-- Considerations of a fully automated cell manufacturing process
-- Process transfer and decentralized manufacturing strategies of CAR T cells
Dr. Hermann Bohnenkamp, VP Business Development APAC, Miltenyi Biotec

From Compelling to Propelling: The Drive to Accelerate Cell and Gene Therapies to Market
-- Global progress and momentum in the cell and gene therapy market
-- Needs and challenges for various stakeholders on the path to commercialization
-- Collaboration to drive standardization in the industry
Dr. Delara Motlagh, Vice President, Cell Therapy Technologies, Terumo BCT

Evolution in the Manufacturing of Cellular Therapies - Lessons Learned and Current Solutions
Abstract: Immunotherapy is a powerful treatment that harnesses the body’s immune system in the fight against cancer. With optimized cell therapy, the result is an expanded population of T cells primed to recognize and eradicate malignant tumor cells that would otherwise escape immune detection.
-- Commercialization of manufacturing- preparing a CAR Garage, lessons learned and how does it impact the patient.
-- Automated functional testing- fully integrated unit operations taking the art out of science!
Dr. Neil Kayal, Global BioPharma Manager - Cell and Gene Therapy Commercialization, Beckman Coulter

Platform Technology to Scale Up CAR-T to Commercial Manufacturing
-- QbD implementation in CAR-T on process development and process characterization
-- single use technologies for closure system and risk mitigation
-- single use technologies quality risk management
-- technologies for data management, in-process control and release testing
Mr. Shen Liang, Manager of Platform Development Specialists, Sartorius Stedim ( Shanghai )

Automated Manufacturing of Chimeric Antigen Receptor T Cells
The chimeric antigen receptor gene-modified T cells (CAR-T cells) technology has been proven clinically successful since 2010, especially targeting CD19 molecules in the treatment of refractory, relapsed B cell-derived malignancies in which the clinical efficacy has never been achieved by traditional tumor therapy strategies, and become the most attractive area in cancer immunotherapy. However, CAR-T cell technology has been experiencing huge challenges, including the expensive preparation and quality control costs for CAR-T cells and lacking clinically verified automated and closed technology. In another word, current mainstream technology hugely relies on highly skillful personnel that increases risk of contamination and production failure, and brings uncertainty for its industrialization. In this presentation, Dr. Yang will analyze the development trend based on his team’s effort in this area, and summarize how applying automated platform to CAR-T cell manufacturing will prompt CAR-T cell technology industrialization and lead to clinical success.
Dr. Lin Yang, Chief Executive Officer, PersonGen BioTherapeutics (Suzhou) Co., Ltd

Advancing Cellular Therapies with a cGMP-Compliant Non-viral Cell Engineering Platform
Abstract: The field of cellular therapy has advanced rapidly in recent years due to the emergence of precision tools for genome modification. Chimeric antigen receptors and CRISPR/Cas9 gene editing reagents are enabling researchers and clinicians to target T cells and NK cells to diseased tissues and to engineer phenotypic changes that were unimagined only a few years ago. Although cell and gene therapies have been approved by the FDA, it remains imperative that researchers consider early in development whether their cell engineering method meets the stringent demands of clinical use - - namely the ability to safely and reproducibly modify human primary or stem cells with high efficiency, low cytotoxicity, and at the scale required to treat patients. MaxCyte’s ExPERT platform, a non-viral cell engineering technology designed to fulfill these demands, has an established record of rapidly advancing cell- and gene-based therapies to the clinic. This presentation will highlight the high efficiency, high viability, fully scalable engineering of a variety of primary hematopoietic cells, stem cells and hiPSCs as well as their real-world application in pre-clinical disease modeling and IND-enabling studies for the therapeutic correction of monogenic disease mutations such as X-linked chronic granulomatous disease (X-CGD) and sickle cell disease (SCD).
Dr. James Brady, Vice President of Technical Applications and Customer Support, MaxCyte

Cell Based Therapies: Key Considerations for Clinicians, Health Care Systems, International Societies and Regulatory Authorities
- Landscape of cell therapy in Asia
- Initiative for Cell therapy in Singapore
- Cell therapy Trials in Singapore and Asia
- Regulatory convergence
- Unproven therapies
Dr Mickey Koh, Director-Stem Cell Transplantation, Consultant Haematologist/Hon Senior Lecturer, St George’s Hospital and Medical School, London, UK
Programme and Medical Director, Cell Therapy Programme, Health Sciences Authority, Singapore

Revolution of CAR-T Cell Therapies – Regulatory and Commercialization Considerations for Yescarta in China
Dr. Richard Wang, Chief Executive Officer, Fosun Kite Biotechnology Co., Ltd

The preliminary results of the first-in-class dnPD1 “Armored” CAR-T proof of concept clinical study in r/r NHL patient
-- An introduction of the dominant negative PD1 platform technology
-- The pre-clinical data of ICTCAR014
-- Preliminary clinical data of ICTCAR014
Dr. Lei Xiao, Chairman & CSO, Innovative Cellular Therapeutics CO., LTD

CD19 CAR-T Treatment for R/R B-cell ALL
-- Summarize the development of CAR T cell therapy for hematological malignancies
-- Display clinical outcomes of CD19 CAR T treatment in R/R B-cell ALL including a large cohort of high-risk subgroups in our center
-- Compare the effects of CD19+CD22 to CD 19 CAR T for R/R B-cell ALL patients
-- Explain the benefits from bridging into transplant after CAR-T for B-cell ALL patients
Dr. Peihua (Peggy) Lu, Medical Executive President, Lu Daopei Hospital, Beijing, Lu Daopei Institute of Hematology

Development of next-generation CAR-T cells in China
-- Problems of current CAR-T cell therapeutics in clinic
-- Innovative safety switch for CAR-T cells
-- Next-generation of CAR-T cells with increased antitumor activities
Dr. Zonghai Li, Chief Executive Officer, Chief Scientific Officer, CARsgen Therapeutics

Key considerations in developing Anti-AFP (TCR-mimic) Artemis T Cell product for HCC in China
-- Major Challenges for CAR-T therapy in solid tumors, especially in HCC
-- Developing investigator-initiated clinical study of using anti-AFP Artemis T cell to treat patients with HCC in China
-- Key considerations in translating and developing anti-AFP Artemis T cell product for IND and commercialization in China
Dr. Yu Zhang, Co-Founder and Chief Executive Officer, Aeon Therapeutics Co., Ltd

FasT CAR-T – breakthrough technology for hematological malignancies
Abstract: Chimeric antigen receptor T cell (CAR-T) therapy has been a success in treating acute
lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). However, the therapeutic potential can still be further improved. In addition, long manufacturing time and high cost of CAR-T product limit the wider applications of CAR-T therapy. We have developed a new manufacturing platform, FasT CAR-T, in that the manufacturing time is shortened to one day (plus 7 days for releasing tests per regulatory requirement) as compared to the conventional CAR-T manufacturing time of 9-14 days plus 7 days. Hence the FasT CAR-T’s vein-to-vein time is shortened by an average of 12 days, which is critical for patients with rapidly progressing disease. More importantly, CD19-directed FasT CAR-T has been shown to have superior expansion capability, younger and less exhausted phenotype, and higher potency in eliminating B-ALL and NHL both in vitro and in vivo. First-in-human clinical study is ongoing and the early results show that FasT CAR-T is safe, and significantly more potent than the conventionally-manufactured CAR-T.
Dr. Wei (William) Cao, Founder, Chairman and CEO, Gracell Biotechnologies
Dr. Zhang Xi, Director, Chief Physician, Professor, Doctoral Supervisor, Visiting Scholar, Distinguished Professor of Changjiang Scholar, XINQIAO HOSPTIAL, ARMY MEDICAL UNIVERSITY

Revolution for Future I-O Therapy in Breast Cancer
- Immune checkpoint inhibitors (ICI) have been mainstay of therapy of malignant melanoma, lung and a few other cancers now for several years.
- These diseases show very high tumor mutation burden (TMB)
- Breast cancer has overall only an intermediate TMB with triple negative (TN) BrCa somewhat higher
- Finally at ESMO 2018 a study in TN MBC testing nab-Paclitaxel (nab-P) without or with Atezolizumab in 1st line setting has shown an advantage for the combination in PFS and OS
- The future of ICI in BrCa will also hopefully show an advantage in early BrCa (EBC) and with a variety of ICI and other IO therapies hopefully also in HER2 positive and maybe Hormone receptor positive BrCa
Dr. Stefan Glueck, Professor of Medicine, Vice President of Global Medical Affairs and Early Assets, Celgene Corporation

Virus Specific T cell (VST) Platform – Create the Next Generation of Immunotherapies to Treat Solid Tumors
Dr. John Connolly, Chief Scientific Officer, Tessa Therapeutics Pte Ltd

In Situ Vaccination of monoclonal CAR-NK Cells Activates Systemic Immunity Against Tumors
Abstract:This presentation will be introduced from three aspects: Seamless large scale production of CAR-NK, Activation of systemic immunity, and in Situ vaccination to treat solid tumors. We has been focused on developing innovative “off-the-shelf” CAR-NK cell drugs for cancer immunotherapy. The R&D team at ATCG, led by Drs. Huashun Li has been based on natural killer cell line NK-92 as a platform to develop over 15 CAR stably expressing NK cell lines (CAR-NK) to treat different types of solid tumors. The preliminary clinical research studies have shown that ATCG427 CAR-NK therapy yields a remarkable response rate and partly persistent remission in the treatment of over 80% solid tumors including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. ATCG has been well positioned in the fast growing tumor immunotherapy field with the proprietary CAR-NK technology.
Dr. Huashun Li, President and Chief Executive Officer,Asclepius Technology Company Group ( ATCG Corp )

Development of Combined CAR-T Cells in Therapy Against Solid Tumors
Dr. Jianqiang Li, Chairman and Chief Scientific Officer, Senlang Bio

Development of CAR-T targeting hematological malignancies
Dr. Ting He, Chief Executive Officer, ImmunoChina Pharmaceuticals Co. Ltd

FasT CAR-T – breakthrough technology against hematological malignancies
Dr. William Cao, Founder, Chairman and CEO, Gracell Bio

Next generation drug screening based on novel iPSC-derived cardiomyocyte platform
Dr. Kai Zhu, Vice President and co-Founder, Help Stem Cell Innovation Ltd

Working Together for Better Health -- Partnering with Boehringer Ingelheim
Dr. Weiyi Zhang, Director of External Innovation, China, Research Beyond Borders, Boehringer-Ingelheim Pharma

Translational models of dysmetabolism and diabetes and the complications (nephropathy, cardiomyopathy, and NASH): from rodents to nonhuman primates
Abstract: The translational values of the animal models for cardiovascular and metabolic diseases as well as their complications, such as nephropathy, cardiovascular disorders, NASH, etc., have long been an important topic for the pharmaceutical and academia research. The upcoming Webinar will introduce the new generation models of these models and comparison with the traditional models for their advantage and limitations, as well as the applications in R&D.
Dr. Jim Wang, SVP, Cardiovascular and Metabolic Disease Research, CrownBio

Growth in Quality of Innovation – A Perspective about Innovative Drug Discovery in China
This presentation will highlight the key components underlying the vibrant innovation ecosystem of drug discovery and development in China. Specifically, examples of the drug discovery projects at Roche Innovation Center Shanghai will be used to showcase how MNCs in China move first-in-class/best-in-class potential programs forward through internal innovation and external collaboration. Finally, Roche’s external collaboration strategy and efforts in China will be summarized at a high level.
- Ecosystem fosters drug discovery and development in China
- Challenges & opportunities in innovative drug discovery and development in China
- Innovative drug discovery highlights from Roche Innovation Center Shanghai
- External collaboration in China
Dr. Hong Shen, Site Head, Head of Medicinal Chemistry, Head of External Innovation, Therapeutic Modalities, Roche Innovation Center Shanghai

Discovery of Immuno-Oncology Small Molecule Drugs in China
- Introduction of immune checkpoint therapies in combination with small molecule therapies
- Discovery and development of GFH018 as a potent and bioavailable TGFbR1 inhibitor for IO therapy
Dr. Jiong Lan, Co-founder and CEO, GenFleet Therapeutics Inc

Productive Collaboration of Big Pharma and CRO: the Integrated Service which Produced Two Clinical Drugs for IBS
Abstract: The integrated service project team led by me at of WuXi Apptech had worked closely with GSK VPOC BU in drug discovery. WuXi team were responsible for medicinal chemistry including design and all compound synthesis, biological testing, and DMPK. We together delivered 3 PPC from scratch with two entered clinical trials. The collaboration was very successful and cost-efficient.
-- Introduction of GSK VPOC business unit and the Integrated service division of WuXi Apptech IDSU
-- Collaboration model and agreements
-- Project : RET kinase inhibitor as treatment for IBS
-- Results: drugs, patents, and publications
Dr. Huiping Amy Guan, VP and Head of Chemistry, Haiyan Pharma of Yangzi River Pharmaceuticals

BeyondSpring’s Global Plinabulin Clinical Development and Cooperation in China
Dr. Lan Huang, Chief Executive Officer & Co-Founder, BeyondSpring Pharmaceuticals, Inc

CMC Challenges in Drug Development of Precision Medicine and How Building Blocks Focused Strategy, Consistent Quality and Use of New Technologies Help
Dr. Shijie Zhang, Chief Technology Officer, PharmaBlock

Cancer Immunotherapy & R&D Innovation
-- Current cancer IO status
-- Challenges and opportunities
-- Next breakthrough in cancer treatment (R&D)
Dr. Ruirong Yuan, President, Chief Medical Officer and Board Director, Adlai Nortye Biopharm


Global Leaders Fireside Chat: Revolution in Future Cancer Immunotherapies and How Will it Scale over the Next Decades

Dr. Renier Brentjens, Director, Cellular Therapeutics, Associate Chair, Junior Faculty Development, Department of Medicine, Memorial Sloan-Kettering Cancer Center

Dr. Eric Smith, Assistant Attending Physician - Myeloma Service, Director of Translational Development - Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Dr. Mickey Koh, Director-Stem Cell Transplantation, Consultant Haematologist/Hon Senior Lecturer, St George’s Hospital and Medical School, London, UK
Medical Director, Cell Therapy Facility, Division Director and Consultant Hematologist, Health Sciences Authority, Singapore
Dr. Wan-Jin Hong, Professor and Executive Director, IMCB (Institute of Molecular and Cell Biology), A*STAR, Singapore Immunology Network
Dr. Stefan Glueck, Professor of Medicine,VP of Global Medical Affairs and Early Assets, Celgene Corporation
Dr. Hequn Yin, CSO , FOSUN Pharma

Panel Discussion: Establishing a Robust, Scalable, Automated, Functionally-closed Manufacturing Process to Support a Pipeline of Emerging CAR-T Cell Immunotherapy Market in China

Dr. Yang Lin, Chief Executive Officer, PersonGen BioTherapeutics, Anke Cellular Therapeutics
Dr. Richard Wang, Chief Executive Officer, Fosun Kite Biotech
Dr. Frank Fan, Chief Scientific Officer and Co-Founder, Legend Biotech
Dr. Lei Yu, Chief Executive Officer, UniCAR-Therapy Bio-Medicine Technology
Dr. Zonghai Li, Chief Executive Officer, Chief Scientific Officer, CARsgen Therapeutics

Panel Discussion: Development Next Generation CAR T-Cell Therapy and Off-shelf CAR-NK Cell Therapy in China

Dr. Cheng Liu, Founder and Chief Executive Officer, Eureka Therapeutics
Dr. Ting He, Chief Executive Officer, Immuno China Biotech
Dr. Yu Zhang, Co-Founder and Chief Executive Officer, Aeon Therapeutics
Dr. Xiaodong Song Vice General Manager, HRAIN Biotechnology
Dr. Huashun Li, President and Chief Executive Officer, Asclepius Technology Company Group ( ATCG Corp )
Dr. Jianqiang Li, Chairman & Chief Scientific Officer, Senlang Bio

Regional Pharma R&D Leaders Roundtable: Developing the Strategic and Innovative Partnership Model in Asia & China

Dr. Hong Shen, Site Head, Head of Medicinal Chemistry, Head of External Innovation, Therapeutic Modalities,Roche Innovation Center Shanghai
Dr. Xichen Lin, Head of R&D Innovation Sourcing Asia Pacific,Novo Nordisk
Dr. Bin Li, Director, Search & Evaluation, JAPAC, AbbVie China
Dr. Xiang Yang Zhu, CEO,Huaota BioPharm and Huabo Biopharm
Dr. Wan-Jin Hong, Professor and Executive Director, IMCB (Institute of Molecular and Cell Biology), A*STAR
Prof. Jonathan B. Baell, NHMRC Principal Research Fellow, Director,Australian Translational Medicinal Chemistry Facility
Larkins Fellow, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences,Monash Institute of Pharmaceutical Sciences, Monash University (Parkville Campus)


Strengthening Global Collaboration and Partnership for AI in Healthcare (R&D and Care Delivery)
-- Offer current landscape, trends and promise for AI innovation in healthcare sector
-- Includes highlight of challenges and efforts underway
-- Introduces AAIH as it seeks to unify industry to help accelerate and promote AI and Machine Learning Platforms and Healthcare applications
Dr. Annastasiah Mudiwa Mhaka, Co-Founder and President Alliance for AI in Healthcare (AAIH), Sr. Advisor Adjuvant Partners

AI for Longevity and Drug Discovery
Talk description: Recent advances in artificial intelligence provide new opportunities in every segment of drug discovery including hypothesis generation, omics analysis, target identification, hit identification, compound generation, ADME Tox, clinical trials enrollment and management, personalized medicine, real world evidence and marketing. While most of the companies and academics tend to specialize in one of these specific fields, some pursue the end-to-end drug discovery approach. The talk will cover the recent progress in the end-to-end pipeline development at Insilico Medicine and recent advances in the generative adversarial networks (GANs) and reinforcement learning (RL) for generation of novel chemistry in close collaboration with WuXi AppTec, identification of novel biological targets and real world evidence collection and analysis. The talk will focus on the recent collaborations with WuXi and the opportunities presented by AI in small molecule drug discovery area.
Dr. Alex Zhavoronkov, Founder and CEO, Insilico Medicine, Inc

Applying Computational Chemistry Techniques to Accelerate New Drug Discovery
Abstract: Molecular docking is now one of the most pragmatic techniques to leverage protein structure for ligand discovery. To strike the balance of efficiency and accuracy, we have systematically improved the accuracy and efficiency of molecular docking by developing a hierarchical strategy to integrate different computational methods in an increasing order of complexity and more physically realistic manner. We here fairly convincingly show that we have arrived at a computational protocol that is effective to discover novel chemotypes conferring new biology. We will demonstrate our applications in different aspects, namely, identifying new lead series for old targets, predicting unknown polypharmacology of old drugs and discovering the first-in-class druggable candidates against novel biological targets. Finally, we will discuss our progress in the evaluation and optimization of our identified novel candidates in the areas of treating obesity associated metabolic diseases and irritable bowel syndrome through a multidisciplinary approach from mechanistic studies to animal models.
-- Molecular Mechanics
-- Quantum Mechanics
-- Molecular Docking
-- Scoring Function
Dr. Niu Huang, Professor and Principle Investigator,National Institute of Biological Sciences ( NIBS )

The study of drug MOAs based on artificial intelligence
Abstract: With the accumulation of chemical and biological big data, artificial intelligence is more and more playing an important role in drug discovery. This report discusses how to predict adverse drug reactions, study the MOA of drugs, perform ADMET evaluation and make target fishing of natural products based on artificial intelligence. (1) A multiple evidence fusion (MEF) method was developed for the large-scale prediction of drug ADRs and drug-target interactions. MEF is based on the similarity reference by collaborative filtering, and integrates multiple similarity measures from various data types, taking advantage of the complementarity in the data. We used MEF to integrate drug-related/target-related /ADR-related data from multiple levels, including the network structural data formed by known drug–ADR/drug-target relationships for predicting likely unknown ADRs and drug-target interactions. (2) A web-based platform called ADMETlab was developed for systematic ADMET evaluation of chemicals based on a comprehensively collected ADMET database consisting of 288,967 entries. (3) An iterative target screening strategy was developed to de-orphan the neferine by combing different target fishing methods. The proposed computational methods could be used for complementary hypothesis generation and rapid analysis of potential mode of action of drugs.
Dr. Dong-Sheng Cao, Professor and Principal Investigator,Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, P.R. China

Big Data Analytics in Healthcare and Opportunities of AI Innovation
Abstract: This talk will discuss the real world big data ( RWBD ) and advanced analytics such as ML/AI approaches that are uniquely presented in healthcare setting and pharmaceutical industry, including:
-- Strategic road map of applying big data analytics in full life cycle of medicines development spanning R&D and commercialization
-- Discussions of use cases in implementing big data analytics in AstraZeneca for insight generation and decision making
-- Conclusion by presenting the unique opportunities of AI Innovation
-- Summarizing of key takeaways in the era of big data analytics and innovating ML/AI applications in healthcare and pharmaceutical industry
Dr. Xia Wang, Director, Healthcare Informatics, Advanced Analytics Center, Biometric & Information Science, Global Medicines Development, AstraZeneca

Initi-IO: An Integrative and Intelligentized Immuno-Oncology Study Platform
In this talk, we will briefly introduce our recently developed integrative and intelligentized immuno-oncology study platform, i.e., initi-IO, which including the following three modules, (1) AI-based tumor neoantigen identification, (2) tumor immuno-checkpoint response prediction, and (3) small molecule repositioning for immuno microenviorment regulation. initi-IO applied the state-of-the-arts AI and omic-integration techniques for immuno oncology study and hopefully it will provide novel clues and help to accelerate the tumor immuno-therapy.
Dr. Qi Liu, Professor, Bioinformatics Department, Tongji University

AI based Drug Development in Treating Obesity, Hyperuricemia and Aging
The drug development field is lacking a computational tool to predict the function of small molecules of potentials in treating particular diseases. Using artificial intelligence (AI), we developed a hybrid neural network model that links chemicals to target, biomarkers and metabolic flux change of diseases or ADRs. The model is able to predict the chemical function of small molecule drugs against various diseases and conditions including obesity, hyperuricemia, and aging. Experiments directly performed in mice after computation verified the model's predictions with accuracy of ~60% in dozens of samples. We are currently developing models against Alzheimer's disease, non-alcoholic fatty liver disease (NAFLD), stem cell reprogramming, epilepsy and etc. Integrated with a reinforcement learning network, ab initio designed small molecules with higher scores were generated by a specialized DQN network. The properties of designed molecules, including SA, logP, liver/heart toxicity, ADR, anti-oxidant potential etc, then would be evaluated by separate neural network predictors. The proper candidate would be synthesized and tested in animal models.
Prof. Zhengwei Xie, Founder, GigaCeuticals Co., ltd

Apply AI to accelerate Antibody Drug Development
-- Using proprietary B-epitope analysis software AbEpiMax, we have generated >10,000 antibodies against over 5000 different targets successfully;
-- Identification of DKK2 as I/O target by generation of neutralizing mAbs using synthetic peptides as immunogens;
-- Examples will be shared on AI-powered engineering of antibodies for less immunogenicity and better developablity.
Dr. Le Sun, President & CEO, Adjunct Professor, AbMax Biotechnology

Machine Learning in Clinical and Biomarker Data Analysis
In this talk, we will give an overview of the common tasks in biomarker and clinical data exploration and showcase how machine learning methods meet the challenges in different types of analysis. We will focus on three topics: (1) patient subgroup identification for precision medicine; (2) gene signature development from omics data; (3) connectivity map based drug repurposing. We will summarize our talk by providing good practice guidelines for clinical and biomarker data analysis.
Dr. Jie Cheng, Director, Biomarker and Exploratory Analysis, Abbvie Inc

Asia Pharma R&D Leaders Summit 2019  |  Telephone: +86 21 6172 6970  |  E-mail:
© Asia Pharma R&D Leaders Summit 2019 – All rights reserved